Correlation Between Serum Hepatitis B Virus Core-Related Antigen and Intrahepatic Covalently Closed Circular DNA in Chronic Hepatitis B Patients

被引:182
作者
Suzuki, Fumitaka [1 ]
Miyakoshi, Hideo [2 ]
Kobayashi, Mariko [3 ]
Kumada, Hiromitsu
机构
[1] Toranomon Gen Hosp, Dept Hepatol, Minato Ku, Tokyo 1058470, Japan
[2] Fujirebio Inc, Div Res & Dev, Tokyo, Japan
[3] Toranomon Branch Hosp, Dept Res, Inst Hepatol, Kawasaki Ku, Kanagawa, Japan
关键词
HBV DNA; HBcrAg; cccDNA; HBsAg; lamivudine; entecavir; LAMIVUDINE THERAPY; ENZYME-IMMUNOASSAY; GENOTYPE-B; WILD-TYPE; EMERGENCE; INFECTION; CESSATION; PREDICTOR; EFFICACY; MARKER;
D O I
10.1002/jmv.21339
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Nucleos(t)ide analogues are utilized for the treatment of chronic HBV infection, and HBe seroconversion and HBV DNA levels are commonly used as markers of viral status and as primary treatment endpoints. Recently, a new assay was prepared for the detection of serum HBV core-related antigen (HBcrAg), consisting of HBcAg, HBeAg, and p22cr, which is a precore protein from amino acid -28 to at least amino acid 150, by coding the precore/core region. In this study, we examined the correlation between serum HBcrAg concentration and viral status by the analysis of serum HBeAg, HBsAg, peripheral HBV DNA, and intrahepatic covalently closed circular DNA (cccDNA) in 57 chronic hepatitis B patients. Intrahepatic cccDNA was detected in all 57 patients, 42 patients were HBcrAg-positive, and serum HBcrAg concentration level was closely correlated with cccDNA. Additionally, positive HBcrAg concentration level results were observed in 6 out of 13 HBsAg seroclearance patients and 20 out of 31 HBV DNA-negative patients. Moreover, the correlation between HBcrAg and cccDNA in these 31 HBV DNA-negative patients was statistically significant (r=0.482, P=0.006). These data suggest that serum HBcrAg concentration is well correlated with intrahepatic cccDNA level, and that the measurement of serum HBcrAg may be clinically useful for monitoring intrahepatic HBV viral status, especially in patients under treatment with nucleos(t)ide analogues. J. Med. Virol. 81:27-33, 2009. (c) 2008 Wiley-Liss, Inc.
引用
收藏
页码:27 / 33
页数:7
相关论文
共 26 条
[1]   Long-term presence of HBV in the sera of chronic hepatitis B patients with HBsAg seroclearance [J].
Arase, Yasuji ;
Suzuki, Fumitaka ;
Suzuki, Yoshiyuki ;
Saitoh, Satoshi ;
Kobayashi, Masahiro ;
Akuta, Norio ;
Someya, Takashi ;
Hosaka, Tetsuya ;
Sezaki, Hitomi ;
Sato, Junko ;
Kobayashi, Mariko ;
Ikeda, Kenji ;
Kumada, Hiromitsu .
INTERVIROLOGY, 2007, 50 (03) :161-165
[2]   Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy [J].
Chayama, K ;
Suzuki, Y ;
Kobayashi, M ;
Kobayashi, M ;
Tsubota, A ;
Hashimoto, M ;
Miyano, Y ;
Koike, H ;
Kobayashi, M ;
Koida, I ;
Arase, Y ;
Saitoh, S ;
Murashima, N ;
Ikeda, K ;
Kumada, H .
HEPATOLOGY, 1998, 27 (06) :1711-1716
[3]   In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-β-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-β-L-arabinofuranosyluracil [J].
Chin, R ;
Shaw, T ;
Torresi, J ;
Sozzi, V ;
Trautwein, C ;
Bock, T ;
Manns, M ;
Isom, H ;
Furman, P ;
Locarnini, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (09) :2495-2501
[4]   Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection [J].
Colonno, RJ ;
Genovesi, EV ;
Medina, I ;
Lamb, L ;
Durham, SK ;
Huang, ML ;
Corey, L ;
Littlejohn, M ;
Locarnini, S ;
Tennant, BC ;
Rose, B ;
Clark, JM .
JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (10) :1236-1245
[5]  
Dhédin N, 1998, TRANSPLANTATION, V66, P616
[6]   A PRELIMINARY TRIAL OF LAMIVUDINE FOR CHRONIC HEPATITIS-B INFECTION [J].
DIENSTAG, JL ;
PERRILLO, RP ;
SCHIFF, ER ;
BARTHOLOMEW, M ;
VICARY, C ;
RUBIN, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (25) :1657-1661
[7]   Lamivudine as initial treatment for chronic hepatitis B in the United States [J].
Dienstag, JL ;
Schiff, ER ;
Wright, TL ;
Perrillo, RP ;
Hann, HWL ;
Goodman, Z ;
Crowther, L ;
Condreay, LD ;
Woessner, M ;
Rubin, M ;
Brown, NA .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (17) :1256-1263
[8]   Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine [J].
Hatakeyama, Tsuyoshi ;
Noguchi, Chiemi ;
Hiraga, Nobuhiko ;
Mori, Nami ;
Tsuge, Masataka ;
Imamura, Michio ;
Takahashi, Shoichi ;
Kawakami, Yoshiiku ;
Fujimoto, Yoshifumi ;
Ochi, Hidenori ;
Abe, Hiromi ;
Maekawa, Toshiro ;
Kawakami, Hiroiku ;
Yatsuji, Hiromi ;
Aisaka, Yasuyuki ;
Kohno, Hiroshi ;
Aimitsu, Shiomi ;
Chayama, Kazuaki .
HEPATOLOGY, 2007, 45 (05) :1179-1186
[9]  
Hui CK, 2006, GASTROENTEROLOGY, V131, P59, DOI 10.1053/j.gastro.2006.04.015
[10]  
Ikeda K, 2006, AM J MED, V119, P977, DOI [10.1016/j.amjmed.2006.04.036, 10.1016/j.amjmed.2005.02.033]